Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient

Oncology Letters

Volumn 4, Issue 2, 2012, Pages 252-256

  Chanvorachote, Pithi ^a   Luanpitpong, Sudjit ^b   Chunhacha, Preedakorn ^b   Promden, Worrawat ^a   Sriuranpong, Virote ^c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b Pharmaceutical Technology (International) Program   (Thailand)

^c KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Cancer associated antigen 125; Cisplatin; Lung cancer; Thai

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; CYTOKERATIN 19; SQUAMOUS CELL CARCINOMA ANTIGEN;

AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CASE REPORT; CELL GROWTH; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; LUNG CANCER; MACROPHAGE; MALE; PLEURA EFFUSION; PROTEIN EXPRESSION; SOLID TUMOR; THAILAND; TREATMENT RESPONSE;

EID: 84861989699     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.711     Document Type: Article

References (19)

1. Pamies RJ and Crawford DR: Tumor markers-an update. Med Clin N Am 80: 185-199, 1996.
2. Trape J, Molina R and Sant F: Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential of serous effusions. Tumor Biol 25: 276-281, 2004.
3. Hayes DF, Bast R C, Desch CE, et al: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer I 88: 1456-1466, 1996.
4. Zurawski VR Jr, Knapp R C, Einhorn N, et al: An initial analysis of preoperative serum CA 125levels in patients with early stage ovarian carcinoma. Gynecol Oncol 30: 7-14, 1988.
5. Bast RC Jr, Klul TL and St John E: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med 309: 883-887, 1983.
6. Kimura Y, Fujii T, Hamamoto K, et al: Serum CA125level is a good prognostic indicator in lung cancer. Brit J Cancer 62: 676-678, 1990.
7. Homma S, Satoh H, Kagohashi K, et al: Production of CA125by human lung cancer cell lines. Clin Exp Med 4: 139-141, 2004.
8. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl J Med 350: 351-360, 2004.
9. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005.
10. Wang L, Chanvorachote P, Toledo D, et al: Peroxide is a key mediator of Bcl-2down-regulation and apoptosis induction by cisplatin in human lung cancer cells. Mol Pharmacol 73: 119-127, 2008.
11. Wu YJ, Muldoon LL and Neuwelt EA: The chemoprotective agent N-acetylcyseine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312: 424-463, 2005.
12. Gilliland FD: Ethnic differences in cancer incidence: a marker for inherited susceptibility? Environ Health Persp 105: 897-900, 1997.
13. O'Donnell PH and Dolan ME: Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 15: 4806-4814, 2009.
14. Musuda N, Fukuoka M, Takada M, Kudoh S and Kusunoki Y: Establishment and characterization of 20human non-small cell lung cancer cell lines in a serum-free defined medium (ACL-4). Chest 100: 429-438, 1991.
15. Vatanasapt V, Sriamporn S and Vatanasapt P: Cancer control in Thailand. Jpn J Clin Oncol 32: S82-S91, 2002.
16. Read C, Janes S, George J and Spiro S: Early lung cancer: screening and detection. Prim Care Respir J 15: 332-336, 2006.
17. Buccheri G and Ferrigno D: Lung tumour markers in oncology practice: a study of TPA and CA125. Brit J Cancer 87: 1112-1118, 2002.
18. Jacobs IJ, Skates SJ, MacDonald N, et al: Screening for ovarian cancer: a pilot randomized controlled trial. Lancet 353: 1207-1210, 1999.
19. Pabla N and Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73: 994-1007, 2008.